Clinical Trial Update: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE) [Phase 2]

View source ↗

Summary

Phase 2 trial of 64Cu-SAR-BBN for identifying recurrence of prostate cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 64Cu-SAR-BBN

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate | Phase 2 | Status: COMPLETED | Results posted: 2025-11-17